Stanford neuroscientist and podcast host Andrew Huberman told the a16z team that the peptide space has reached a point of no return. During the podcast conversation, Huberman stated that within five years, highly personalized peptide cocktails will be as unremarkable to the average person as taking vitamin D or creatine.
Huberman outlined a future where individuals take a tailored daily blend, morning and night, calibrated to their specific biological needs.
“I think in five years you and I are going to have a little cocktail,” he said. “It’s going to be one injection or one pill and it’s going to be a little bit of pinealin at night combined with something else. It’s going to be in the morning, something, whatever it is that you need to ramp up your dopaminergic system a little bit to make sure that I’m getting enough micronutrients. Maybe I’m going to put a little something in there to protect me against Alzheimer’s. I think all of that stuff is going to be commonplace.”
Huberman drew a direct parallel to how public perception shifted around fitness supplements over the past few decades. Just as creatine and magnesium moved from the fringes of gym culture to mainstream acceptance, he argued that peptides are following the same trajectory toward normalization.
“The same way that people are not afraid of vitamin D or they’re taking some creatine or magnesium. People taking magnesium is kind of the next wave of of accepted supplements I think that feel safe enough,” he said.
The cost, he argued, will also fall low enough that access will no longer be limited to early adopters or the wealthy.
Central to his forecast is the continued rise of GLP-1 treatments and next-generation therapies like Retatrutide.
He also pointed to compounding pharmacies and gray market sources as the current engine of adoption, noting that people are already self-experimenting with lower doses than officially prescribed, with some reporting reduced al**hol cravings and less cognitive noise as side effects.
